EURAP is a prospective observational study
of pregnancies with antiepileptic drugs

The well-being of women with epilepsy and their offspring is of great concern. Our aim is to contribute to a better understanding of the risks associated with antiepileptic drugs during pregnancy.

What we need is the collaboration of physicians from all corners of the world to join forces.


he primary goal is to compare the risk of major congenital malformations following maternal

Why a pregnancy registry?

The use of AEDs during pregnancy is associated with an increased risk of birth defects.

Funding and support

EURAP is an independent research initiative promoted and implemented by physicians working

It was launched in Europe in 1999 by a consortium of independent research groups and later extended to several other nations worldwide. The aim was to collect data on the risk of antiepileptic drugs during pregnancy and share it in an international registry.

At present, physicians from 42 countries in Europe, Oceania, Asia, Latin America and Africa are actively collaborating, and more than 24,000 pregnancies have been registered.

0 enrolled pregnancies
42 countries from Europe, Australia, Asia, South America

Stay tuned and do not miss the chance to collaborate.